ALFA Finder| Management target | Revenue 12.5% FY27 |
|---|
| Revenue growth | 11.3% YoY growth in Q1FY27. |
|---|---|
| Margins | EBITDA margins targeted at 18-20% for FY27/28. |
| Demand visibility | Strong domestic API demand; export recovery expected over the year. |
| Management confidence | High; projecting stable growth and margin expansion through product mix. |
Growth
Revenue increased 11.3% YoY; Gross margin expanded 210 bps to 48.3%; EBITDA grew to INR 29.6 Cr.
Outlook
Guided 10-15% growth for FY27; INR 40-50 Cr annual capex; new peptide and oncology plants commissioned by 2027-2028.
Risks
Geopolitical conditions affecting export normalization; dependence on stable oil prices for API pricing; high inventory levels.
Investor Presentation filed with BSE, NSE: BAJAJHCARE. Summary written with AI assistance from the document.
Bajaj Healthcare Ltd: key numbers
- Share price
- ₹325.35
- Market cap
- ₹1,095 Cr
- Revenue (annual)
- ₹611.0 Cr
- Net profit (annual)
- ₹15.77 Cr
- P/E (TTM)
- 53.1×Sector 43.8×
- Promoter holding
- 58.59%+0.00% QoQ
- FII holding
- 2.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bajaj Healthcare Ltd
All →Bajaj Healthcare Earnings Call Transcript: Key Takeaways
Bajaj Healthcare delivered strong H1 growth led by a 82% surge in formulations and key new specialty launches.
- Call
- Guides 15% growth
Bajaj Healthcare Results Update
Bajaj Healthcare reported Q2 FY27 revenue of ₹175.9 Crore, up 18.9% YoY. EBITDA stood at ₹32.1 Crore, reflecting a 12.2% YoY increase.
Bajaj Healthcare Other Announcement
Bajaj Healthcare filed its Monitoring Agency Report for the quarter ended September 30, 2026, as required by SEBI regulations for the utilization of preferential issue proceeds.
Bajaj Healthcare Q2 FY27 Results: Net Profit ₹14.1 Cr, Up 27.0% YoY
Bajaj Healthcare Ltd reported revenue from operations of ₹175.9 Cr (+18.9% YoY) and net profit of ₹14.1 Cr (+27.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹14.1 Cr · +27.0% YoY
Bajaj Healthcare Acquisition
Bajaj Healthcare received NCLT approval to acquire Genrx Pharmaceuticals Private Limited as a going concern. The entity will become a wholly owned subsidiary.
Bajaj Healthcare Merger & Restructuring Worth ₹14.67 Cr
Bajaj Healthcare Limited has executed a deed of assignment to sell its undertaking located in Dahej Industrial Area, Gujarat, for approximately Rs. 14.67 Crore.
- Value
- ₹14.67 Cr